Chemical Probes for Drug-Resistance Assessment by Binding Competition (RABC): Oseltamivir Susceptibility Evaluation (pages 366–370)
Dr. Ting-Jen R. Cheng, Shi-Yun Wang, Dr. Wen-Hsien Wen, Dr. Ching-Yao Su, Mengi Lin, Wen-I Huang, Dr. Ming-Tsan Liu, Dr. Ho-Sheng Wu, Nung-Sen Wang, Chung-Kai Cheng, Chun-Lin Chen, Dr. Chien-Tai Ren, Dr. Chung-Yi Wu, Prof. Jim-Min Fang, Dr. Yih-Shyun E. Cheng and Prof. Chi-Huey Wong
Article first published online: 13 NOV 2012 | DOI: 10.1002/anie.201204062
The wizard of OS (resistance): The binding difference of neuraminidase inhibitors (zanamivir versus oseltamivir (OS)) was used to establish an assay to identify the influenza subtypes that are resistant to OS but still sensitive to zanamivir (see scheme). This assay used a zanamivir-biotin conjugate to determine the OS susceptibility of a wide range of influenza viruses and over 200 clinical isolates.